Allergies News and Research

Latest Allergies News and Research

SARS virus vaccine stimulates protective immune response

An experimental vaccine prevents the SARS virus from replicating in laboratory mice, according to a new report in the April 1 issue of Nature. Scientists at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health, developed the vaccine. The vaccine was tested in a mouse model of SARS infection recently validated by other NIAID investigators.

31 Mar 2004

Cryptosporidium parvum parasite could help to develope new therapies for the disease

Cryptosporidium parvum, an insidious, one-celled, waterborne parasite that lodges in the intestines of infected people and animals and for which there is currently no effective treatment, is missing key structures normally found in similar parasites, say researchers supported by the National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health. The results of their genome sequencing project, could help scientists home in on new drug targets that may lead to therapies for the disease.

26 Mar 2004

First US Tests of Bird-Flu Vaccine in Humans

Doctors are beginning the first test in the United States of a vaccine designed to protect people against one form of bird flu should an outbreak of the virus occur in humans. While the vaccine under study is not designed to protect against the precise bird-flu virus causing the current outbreak in poultry and in people, scientists will learn whether it protects against another strain of the virus that infects birds and people.

24 Mar 2004

Ban Chlorpyrifos and Diazinonon Impacts Child Birth Weights

A federal ban on two insecticides has resulted in a significant reduction in their impact on newborns' birth weight and length, according to a new study funded by the National Institute of Environmental Health Sciences of the National Institutes of Health, the U.S. Environmental Protection Agency, and other private foundations.

23 Mar 2004

Olopatadine nasal spray shown to minimise hay fever

Alcon announced today results from a Phase III clinical trial demonstrating that olopatadine nasal spray, a nasal formulation of its market leading ophthalmic anti-allergy product, Patanol(R) ophthalmic solution, reduced seasonal allergic rhinitis (SAR) symptoms compared to placebo.

22 Mar 2004

FDA approves new chewable formulation of Zyrtec® aimed at young allergy sufferers

Pfizer Inc and UCB Pharma today announced the approval of a new chewable formulation of Zyrtec® (cetirizine HCl) for the treatment of seasonal and perennial allergic rhinitis (inflammation of the nasal passages) and chronic idiopathic urticaria (itching and hives of unknown causes) in children aged two years and older. The approval by the US Food and Drug Administration makes Zyrtec the first and only prescription antihistamine available in both syrup and chewable form.

22 Mar 2004

Forward step in treatment of Allergic Rhinitis

Rigel Pharmaceuticals, Inc. has announced the presentation of clinical data for R112, the company’s lead candidate for the treatment of allergic rhinitis, during a poster session at the annual meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI) in San Francisco, CA. The phase I/II single dose trial demonstrated that R112 was well tolerated and showed favorable biological effects.

22 Mar 2004

Japanese study raises concerns for childhood health issues

The number of children suffering from mental disorders and health problems such as allergies and asthma has risen sharply over the past decade in this country. The United States and European countries are also facing the increasingly serious problems of premature births and childhood obesity, in addition to allergic reactions. Many experts say the rise in health problems involving children is related to the use of chemicals in our daily lives and the impact of medical treatment provided to the children's mothers.

22 Mar 2004

Mouse antibodies neutralise SARS virus

The mouse immune system develops antibodies capable of single-handedly neutralizing the SARS virus, researchers at the National Institute of Allergy and Infectious Diseases (NIAID) report in the April 1 issue of the Journal of Virology, now available online. NIAID is part of the National Institutes of Health (NIH).

22 Mar 2004